Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactiferon derma is an oral food supplement developed by MEDITRINA Pharmaceuticals for dermatological support, specifically targeting conditions such as acne vulgaris and rosacea. It is formulated as gastro-resistant (enteric-coated) tablets to ensure optimal absorption of its active ingredients in the intestine. The product contains a combination of lactoferrin (100 mg), zinc gluconate (15 mg elemental zinc), nicotinamide (300 mg), and copper (1 mg elemental copper). Lactoferrin, a multifunctional glycoprotein, provides antimicrobial and anti-inflammatory properties, while zinc and nicotinamide contribute to sebum regulation and the reduction of skin inflammation. The supplement is marketed for its antibacterial, anti-inflammatory, and antiseborrheic effects and can be used as monotherapy or as an adjunct to topical or systemic dermatological treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lactiferon derma.